N Engl J Med 1992, 326:1593–1598.PubMedCrossRef
3. al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997, 15:277–284.PubMed 4. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996, 276:637–639.PubMedCrossRef 5. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, see more Satake M, Ishikura S, Ogino T, Miyata Epigenetics inhibitor Y, Seki S, Kaneko K, Nakamura A: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999, 17:2915–2921.PubMed 6. Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, Yamamoto T, Kitahara T, Mizutani check details Y, Ohtsu A, Mitamura K: Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 2003, 88:18–24.PubMedCrossRef 7. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S: Clinical impact of criteria for complete response
(CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005, 35:316–323.PubMedCrossRef 8. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous Prostatic acid phosphatase cell carcinoma of the thoracic esophagus. J Clin Oncol 2003, 21:2697–2702.PubMedCrossRef 9. Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M: Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006, 41:425–432.PubMedCrossRef 10. Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K: Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.
Adv Drug Deliv Rev 2009, 61:388–401.PubMedCrossRef 11. Longley DB, Harkin DP, Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330–338.PubMedCrossRef 12. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998, 16:1470–1478.PubMed 13.